Premium
Hormonal therapy of renal carcinoma alone and in association with cytostatic drugs
Author(s) -
Alberto P.,
Senn H. J.
Publication year - 1974
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197405)33:5<1226::aid-cncr2820330506>3.0.co;2-z
Subject(s) - medicine , hormone , vinblastine , hormonal therapy , carcinoma , renal carcinoma , oncology , endocrinology , urology , chemotherapy , physiology , cancer , breast cancer
In three successive studies, 58 observations of hormonal treatment for renal carcinoma were negative. Twenty‐three patients received androgens, 17 received progestogens, and 20 a combination of androgens, progestogens, 5‐fluorouracil, and vinblastine sulfate. Of those patients treated over 6 weeks, 27 received progestogens and 27 androgens, alone or combined. Although the mortality rate of 58% within the 3 months following the study could account partially for the therapeutic failure, our results suggest that the use of hormonal treatment for renal carcinoma is of little value.